BioNTech (NASDAQ:BNTX) Sees Strong Trading Volume – Time to Buy?

BioNTech SE (NASDAQ:BNTX) shares saw strong trading volume on Tuesday . 254,365 shares changed hands during trading, a decline of 46% from the previous session’s volume of 469,307 shares.The stock last traded at $127.06 and had previously closed at $120.21.

Analyst Ratings Changes

Several research firms recently issued reports on BNTX. UBS Group raised their price target on BioNTech from $97.00 to $131.00 and gave the company a “neutral” rating in a report on Wednesday, September 18th. Canaccord Genuity Group lifted their price target on shares of BioNTech from $171.00 to $171.44 and gave the stock a “buy” rating in a research report on Wednesday, November 27th. Wells Fargo & Company began coverage on shares of BioNTech in a report on Wednesday, December 11th. They issued an “overweight” rating and a $170.00 price objective on the stock. JPMorgan Chase & Co. reduced their price target on BioNTech from $124.00 to $122.00 and set a “neutral” rating on the stock in a research report on Tuesday, November 26th. Finally, HC Wainwright reiterated a “buy” rating and issued a $150.00 price objective on shares of BioNTech in a report on Monday, November 18th. Three equities research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $140.76.

BioNTech Trading Up 6.3 %

The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $30.62 billion, a P/E ratio of -60.82 and a beta of 0.18. The business has a fifty day moving average price of $113.47 and a 200 day moving average price of $102.49.

BioNTech (NASDAQ:BNTX) last released its earnings results on Monday, November 4th. The company reported $0.81 EPS for the quarter, beating the consensus estimate of ($1.26) by $2.07. The firm had revenue of $1.24 billion for the quarter, compared to analysts’ expectations of $514.08 million. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The business’s quarterly revenue was up 38.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.73 EPS. On average, analysts expect that BioNTech SE will post -3.72 earnings per share for the current fiscal year.

Institutional Investors Weigh In On BioNTech

Several hedge funds and other institutional investors have recently added to or reduced their stakes in BNTX. Planning Capital Management Corp grew its holdings in shares of BioNTech by 45,000.0% in the 3rd quarter. Planning Capital Management Corp now owns 451 shares of the company’s stock valued at $54,000 after acquiring an additional 450 shares in the last quarter. Blue Trust Inc. grew its stake in BioNTech by 491.1% in the third quarter. Blue Trust Inc. now owns 467 shares of the company’s stock valued at $55,000 after purchasing an additional 388 shares in the last quarter. GAMMA Investing LLC increased its position in shares of BioNTech by 21.7% during the 3rd quarter. GAMMA Investing LLC now owns 623 shares of the company’s stock worth $74,000 after purchasing an additional 111 shares during the last quarter. Daiwa Securities Group Inc. raised its stake in shares of BioNTech by 430.3% during the 2nd quarter. Daiwa Securities Group Inc. now owns 1,925 shares of the company’s stock worth $155,000 after purchasing an additional 1,562 shares in the last quarter. Finally, Caprock Group LLC acquired a new stake in shares of BioNTech in the 2nd quarter valued at approximately $206,000. 15.52% of the stock is currently owned by institutional investors and hedge funds.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.